This antidepressant has very little in common with any of the current medications approved by the FDA, and represents an effective, unique, and natural approach to depression.
(PRWEB) September 23, 2014
Current synthetic antidepressants share problems that include weight gain, sexual dysfunction, serious withdrawal symptoms, ulcers, heart rhythm changes and seizure risks. (1) Suicide risks may also exist, possibly due to slow effects or to the initial high dosing that is common. (2)
Today Dr. James Schaller announced the patent for a new and unique antidepressant treatment. This antidepressant has very little in common with any of the current medications currently approved by the FDA, and represents a unique type of medication. The patent can be seen at: http://www.freepatentsonline.com/y2006/0069059.html
The patent is the creation of transdermal SAM-e which is a natural substance occurring in the body; it is one of the most important cell chemicals for humans. This new dose delivery design avoids the stomach and intestinal side effects of oral SAM-e, and avoids the large number of expensive and inconvenient pills required for mood recovery. It also allows the B-vitamins that SAM-e uses to work to be part of the formula in a simple patch.
Oral or injectable SAM-e has existed in medical science for many decades and the oral form is now in the majority of American pharmacies. Research exists to support its use to prevent routine arthritis (3, 4), to decrease liver cancer, and to decrease inflammatory chemicals. In contrast to routine antidepressants, transdermal SAM-e works more quickly and is not associated with allergic reactions, weight gain, sexual dysfunction, or withdrawal symptoms. It also does not cause ulcers or other intestinal damage, nor does it increase seizures, harm bone marrow or cause heart rhythm changes. (5, 6, 7)
Transdermal SAM-e has many modes of action, such as fighting depression in three neurotransmitter systems: serotonin, norepinephrine and dopamine.
This patented treatment was created by research physician James Schaller, who specializes in treatment-resistant medical or psychiatric patients, in collaboration with research pharmacists, who designed this formulation over the span of ten years.
Dr. Schaller is an internationally renowned author, research physician, theologian, and part-time clinician specializing in non-surgical, non-cancer treatment failure patients. He has written over two dozen books and top journal papers in diverse areas of medicine, including tick, flea and other infections which cause chronic illness and fatigue. He has 13 books discussing tick, flea and pet infections such as Bartonella and dangerous Babesia. He was also the first to publish a practical cancer breakthrough, now a standard treatment internationally. Dr. Schaller treats people nationally and internationally and tailors his treatment to their unique biochemistry and healing preferences. To learn more, visit http://www.personalconsult.com.
Those with a serious financial interest in purchasing the patent should contact:
James Schaller, MD, MAR, PA
Community Bank Tower
Suite 305
5150 Tamiami Trial N.
Naples, Florida 34103
USA
Phone: 239.263.0133
REFERENCES:
1. What are the real risks of antidepressants? Harvard Mental Health Letter. May 2005.
http://www.health.harvard.edu/newsweek/What_are_the_real_risks_of_antidepressants.htm
2. Brent DA, Gibbons R. Initial dose of antidepressant and suicidal behavior in youth: start low, go slow. JAMA Intern Med. 2014 Jun;174(6):909-11. http://www.ncbi.nlm.nih.gov/pubmed/24781493
3. De Silva V, El-Metwally A, Ernst E, Lewith G, Macfarlane GJ; Arthritis Research UK Working Group on Complementary and Alternative Medicines. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology (Oxford). 2011 May;50(5):911-20.
http://www.ncbi.nlm.nih.gov/pubmed/21169345
4. Kim J, Lee EY, Koh EM, Cha HS, Yoo B, Lee CK, Lee YJ,K Ryu H, Lee KH, Song YW. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther. 2009 Dec;31(12):2860-72. http://www.ncbi.nlm.nih.gov/pubmed/20110025
5. Green T, Steingart L, Frisch A, Zarchi O, Weizman A, Gothelf D. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. J Neural Transm. 2012 Nov;119(11):1417-23.
http://www.ncbi.nlm.nih.gov/pubmed/22678699
6. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70 Suppl 5:18-22. http://www.ncbi.nlm.nih.gov/pubmed/19909689
7. Papakostas GI, Cassiello CF, Iovieno N. Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry. 2012 Jul;57(7):406-13. http://www.ncbi.nlm.nih.gov/pubmed/22762295
